

List of Publications (Publikationsliste) Stand 09-01-2023

Dr. med. Christoph Uleer

A. Vollpublikationen

2001

1. V. Möbus, **C. Uleer**, R. Kreienberg (2001): Systemische Therapie des Zervixkarzinoms. Der Onkologe 7:880-888

2002

2. **C. Uleer**, I. Machill, V. Möbus (2002): Individueller Heilversuch und Therapiefreiheit. Gynäkologische Praxis 26:213-218

2006

3. C. Wüster, I. Lutz, J. Y. Pourfard, **C. Uleer**, G. Felmet (2006): Proprioceptives Vibrationstraining – Physiologische Grundlagen und medizinische Anwendungsbereiche Prevention Anti Aging 2: 496-503

2009

4. **C. Uleer**, K. Samse, N. Uleer (2009): Mammographiescreening Hildesheim – Göttingen – Hameln Breast Care 2009; 4:51-54, DOI: 10.1159/000197353, 10. Februar 2009
5. G. v. Minckwitz, A. du Bois, M. Schmidt, N. Maass, T. Cufer, F. E. de Jongh, E. Maartense, C. Zielinski, M. Kaufmann, W. Bauer, K. H. Baumann, M. R. Clemens, R. Duerr, **C. Uleer**, M.I Andersson, R. C. Stein, V. Nekljudova, and S. Loibl (2009): Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009 Apr 20;27(12):1999-2006

2010

6. **C. Uleer** (2010): Wissenswertes vom SABCS 2009. Bericht vom 32. San Antonio Breast Cancer Symposium; Der Frauenarzt 02 (52): 140-148

2011

7. Georg Richter, **Christoph Uleer**, Thomas Noesselt (2011): Multifocal invasive ductal breast cancer with osteoclast-like giant cells: a case report. Journal of Medical Case Reports 2011, 5:85 DOI:10.1186/1752-1947-5-85

2012

8. **Uleer C**, Yazdan-Pourfard J, Holland B, Bürrig KF, Moisisidis-Tesch C, von Minckwitz G (2012): Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone. Breast Care 2012;7:45-47
9. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Lemin A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators ao **Uleer C** (2012): A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284

2013

10. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM; TEACH investigators ao **Uleer C** (2013): Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 14(1):88-96. DOI:10.1016/S1470-20
11. **Uleer C**, Wagner J, Moisisidis-Tesch C (2013): Relevance of Health Economics in Early Detection of Breast Cancer in Germany – the View of the Professional Association of Practicing Gynecologic Oncologists e.V. (BNGO) Breast Care 2013;8:35-39

2014

12. Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, **Uleer C**, Runde V, Dünnebacke J, Belzl N, Augustin D, Kates RE, Harbeck N; West German Study Group (2014): Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. *Ann Oncol.* 2014 Jan;25(1):75-80. DOI: 10.1093/annonc/mdt505.
13. Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE8, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators ao **Uleer C** (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet.* 2014 Mar 22;383(9922):1041-8. DOI: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12.
14. Von Schumann R, Gluz O, Hofmann D, Kates RE, Clemens M, Reimer T, Liedtke B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi, **Uleer C**, Krabisch P, Augustin D, Harbeck N, Nitz U (2014): Febrile neutropenia (FN) and infections under adjuvant chemotherapy of breast cancer with 6 x TC vs. 4 x EC-4 x Doc: Toxicity data of the WSG planB trial. *Oncology Research and Treatment* 37:14-15 · February 2014.
15. Csef H, Hefner J, Hönig A, Otto C., Schilling J., Sokol C., **Uleer C.** (2014): Optimiertes Management des fortgeschrittenen Mammakarzinoms, Modul Psychoonkologie Pharmawissen aktuell 402708 in best practice onkologie 3-4/2014 Der Gynäkologe 7/2014
16. J Schilling, **C Uleer**, S Busch (2014): Neoadjuvante Chemotherapie bei Mammakarzinom-Patientinnen – die Behandlungsrealität in gynäko-onkologischen Praxen des BNGO. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* 2014; 11 - A106, DOI: 10.1055/s-0034-1375465
17. v Minckwitz, Loibl S, Untch M., Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Houber J, Solbach C, Jackisch C, Kunz G Blohmer JU, Hauschild JM, Fehm T, Nekljudova V, Gerber B for the GBG/AGO-B study groups Investigators ao **Uleer C** (2014): Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44 – GeparQuinto) *Ann Oncol* (2014) Sept 15 DOI: 10.1093/annonc/mdu455
18. EM Grischke, D Lüftner, F Schütz, P Wimberger, F Förster, T Decker, **C Uleer**, M Muth, J Kreuzeder, W Bloch, H Tesch, C Jackisch, PA Fasching (2014): Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women – Ergebnisse der ersten Interimsanalyse der nicht-interventionellen Studie BRAWO. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* 2014; 11 - A43, DOI: 10.1055/s-0034-1375402

2015

19. D. Lüftner · E.M. Grischke · P. Fasching · T. Decker · A. Schneeweiss · **C. Uleer** · F. Foerster · P. Wimberger · B. Kluth-Pepper · J. Schubert · W. Bloch · H. Tesch · F. Schuetz · C. Jackisch (2015): 1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO *EJC* Volume 51, Supplement 3, Pages S288–S289
20. E Trapp, B Rack, C Messina, V Müller, T Fehm, W Janni, A Schramm, C Löhberg, P Wimberger, **C Uleer**, O Brudler, C Sotiriou, J Pierga, M Piccart, M Ignatiadis (2015): TREAT CTC – Ein innovativer Ansatz zur Therapie von zirkulierenden Tumorzellen (CTCs) beim frühen Mammakarzinom. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* (2015); 12 - A139, DOI: 10.1055/s-0035-1550581
21. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Collaborators ao **Uleer, C.** (2015): Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol.* 2015 Aug; 16(8):928-36. DOI: 10.1016/S1470-2045(15)00086-8

2016

22. C. M. Moisisidis-Tesch · N. A. Ginsberg · **C. Uleer** · Volker J. Möbus (2016): The Role of Cervical Cultures to Guide Perioperative Antibiotics in Cervical Cerclage- a Retrospective Analysis of 65 Consecutive Cases *Journal of Maternal-Fetal and Neonatal Medicine* · January 2016
23. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Collaborators ao **Uleer, C.** (2016): Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol.* 2016 Jan; 17(1):78-89. DOI: 10.1016/S1470-2045(15)00366-6
24. Tzschaschel, M; Trapp, E; Rack, B; Alunni-Fabbroni, M; Messina, C; Müller, V; Fehm, T; Janni, W; Loehberg, C; Wimberger, P; Lorenz, R; Kolberg, HC; Beck, T; **Uleer, C**; Decker, T; Fett, W; Brudler, O; Sotiriou, C; Pierga, JY; Piccart, M; Ignatiadis, M (2016): Treat CTC: Eine innovative Studie zur Elimination von zirkulierenden Tumorzellen beim primären Mammakarzinom. *Senologie - Zeitschrift für Mammadiagnostik und -therapie*; Ausgabe 02, 2016

2017

25. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators, Collaborators ao **Uleer C**; Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial; *Lancet.* 2016 Feb 27;387(10021):866-73. DOI: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11. PMID: 26686313
26. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators incl. **C. Uleer**; Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer; *N Engl J Med.* 2017 Jul 13;377(2):122-131. DOI: 10.1056/NEJMoa1703643. Epub 2017 Jun 5
27. Bernhardt S, Bayerlová M, Vetter M, Wachter A, Mitra D, Hanf V, Lantzsch T, **Uleer C**, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Thomssen C, Korf U, Beissbarth T, Wiemann S, Kantelhardt EJ; Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors; *Breast Cancer Res.* 2017 Oct 11;19(1):112. DOI: 10.1186/s13058-017-0905-7. PMID: 29020998

2018

28. Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators, Collaborators ao **Uleer C**; Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial; *Lancet Oncol.* 2018 Jan;19(1):127-138. DOI: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17. PMID: 29158011
29. Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, **Uleer C**, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N.; Comparison of Neoadjuvant Nab-Paclitaxel + Carboplatin vs NabPaclitaxel + Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results *J Natl Cancer Inst.* 2018 Jun 1;110(6):628-637. DOI: 10.1093/jnci/djx258. PMID: 29228315

30. Emons G, Steiner E, Vordermark D, **Uleer C**, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Sigurd L, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S. (2018): Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. *Geburtshilfe Frauenheilkd.* 2018 Oct;78(10):949-971. DOI: 10.1055/a-0713-1218. Epub 2018 Oct 19.
31. Emons G, Steiner E, Vordermark D, **Uleer C**, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Lax S, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S. (2018): Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. *Geburtshilfe Frauenheilkd.* 2018 Nov;78(11):1089-1109. DOI: 10.1055/a-0715-2964. Epub 2018 Nov 26.
32. Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribí K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; **SOLE Investigators** (2018): Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2018 Jan;19(1):127-138. DOI: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.
33. **C. Uleer**, B. Alt-Epping, E. Wight, B. vanOorschot, N. Bock, T. Dauelsberg, A. D. Rose, M. Gebhardt, R. Tholen, K. Paradies (2018): Nachsorge, Rezidivtherapie, psychoonkologische Versorgung und Palliativmedizin des Endometriumkarzinoms *Der Gynäkologe*, 51(12), 1037-1046 DOI 10.1007/s00129-018-4338-x
34. **C. Uleer** (2018): 4-Länder-Tagung mit den senologischen Fachgesellschaften aus Österreich, Schweiz, Frankreich und Deutschland *Journal Onkologie Ausgabe 7/8 2018*

2019

35. Bauer M, Kantelhardt EJ, Stiewe T, Nist A, Mernberger M, Politt K, Hanf V, Lantsch T, **Uleer C**, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Wickenhauser C, Thomssen C, Bartel F, Vetter M.: Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. *Oncotarget.* 2019 Mar 8;10(20):1975-1992. DOI: 10.18632/oncotarget.26768. eCollection 2019 Mar 8.
36. Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, **Uleer C**, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, Harbeck N; West German Study Group PlanB Investigators.: West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. *J Clin Oncol.* 2019 Apr 1;37(10):799-808. DOI: 10.1200/JCO.18.00028. Epub 2019 Feb 20

37. Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, **Uleer C**, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N.: Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. *Int J Cancer*. 2019 Jun 4. DOI: 10.1002/ijc.32488
38. Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A; AGO Study Group-led GCIG/ENGOT Intergroup Consortium, AGO-OVAR-12 Collaborators and **Uleer C**: Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. *Int J Cancer*. 2019 Aug 5. DOI: 10.1002/ijc.32606

2020

39. Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators and **Uleer C**: Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2020 May;21(5):699-709. DOI: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. PMID: 32305099 Clinical Trial.
40. Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, **Uleer C**, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N.: Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial; *Int J Cancer*. 2020 Jan 1;146(1):262-271. DOI: 10.1002/ijc.32488. Epub 2019 Jun 19. PMID: 31162838

2021

41. **Christoph Uleer**, Edward Wight, Clemens Tempfer. (2021): Nachsorge des Endometriumkarzinoms. *Der Gynäkologe* 01.02.2021 54; 83-88; DOI: 10.1007/s00129-020-04723-y
42. Noeres D, Sperlich S, Röbbel L, Safieddine B, Deuker JU, Hillemanns P, Ismaél F, Moser A, Noeding KH, Noesselt T, Pape J, Park-Simon TW, Peschel S, Seifert W, Siggelkow W, Thoma M, **Uleer C**, Geyer S. (2021): Predictors of the Utilization and Waiting Period Before Starting an Oncological Rehabilitation after Breast Cancer. *Rehabilitation (Stuttg)*. 2021 Apr;60(2):86-94. DOI: 10.1055/a-1361-4028. Epub 2021 Apr 15. PMID: 33858017 German
43. Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, **Uleer C**, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast (2021): Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). *Ann Oncol*. 2021 Jan;32(1):49-57. DOI: 10.1016/j.annonc.2020.10.471. Epub 2020 Oct 21. PMID: 33098995
44. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and **Investigators**. (2021): Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *N Engl J Med*. 2021 Jun 24;384(25):2394-2405. DOI: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. PMID: 34081848

45. Hartung C, Porsch M, Stückerath K, Kaufhold S, Staeger MS, Hanf V, Lantzsch T, **Uleer C**, Peschel S, John J, Pöhler M, Weigert E, Buchmann J, Bürrig KF, Schüler K, Bethmann D, Große I, Kantelhardt EJ, Thomssen C, Vetter M. (2021): Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. *Breast Care (Basel)*. 2021 Dec;16(6):637-647.
DOI: 10.1159/000519255. Epub 2021 Oct 19. PMID: 35082572
46. Noeres D, Sperlich S, Röbbel L, Safieddine B, Deuker JU, Hillemanns P, Ismaél F, Moser A, Noeding KH, Noesselt T, Pape J, Park-Simon TW, Peschel S, Seifert W, Siggelkow W, Thoma M, **Uleer C**, Geyer S. (2021): [Predictors of the Utilization and Waiting Period Before Starting an Oncological Rehabilitation after Breast Cancer]. *Rehabilitation (Stuttg)*. 2021 Apr;60(2):86-94.
DOI: 10.1055/a-1361-4028. Epub 2021 Apr 15. PMID: 33858017
47. Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching PA, Fehm TN, Hartkopf AD, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Schütz F, Schulmeyer CE, Tesch H, Thomssen C, **Uleer C**, Untch M, Welslau M, Wöckel A, Wurmthaler LA, Würstlein R, Thill M. (2021): Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. *Geburtshilfe Frauenheilkd*. 2021 May;81(5):526-538.
DOI: 10.1055/a-1464-0953. Epub 2021 May 3. PMID: 34035547
48. Ditsch N, Stickeler E, Behrens A, Belleville E, Fasching PA, Fehm TN, Hartkopf AD, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Schütz F, Schulmeyer CE, Tesch H, Thomssen C, **Uleer C**, Untch M, Welslau M, Wöckel A, Wurmthaler LA, Würstlein R, Thill M, Aktas B. (2021): Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers. *Geburtshilfe Frauenheilkd*. 2021 May;81(5):539-548.
DOI: 10.1055/a-1464-1221. Epub 2021 May 3. PMID: 34035548
49. Graeser M, Feuerhake F, Gluz O, Volk V, Hauptmann M, Jozwiak K, Christgen M, Kuemmel S, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, **Uleer C**, Aktas B, Schumacher C, Kolberg-Liedtke C, Kates R, Wuerstlein R, Nitz U, Kreipe HH, Harbeck N. (2021): Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. *J Immunother Cancer*. 2021 May;9(5):e002198. DOI: 10.1136/jitc-2020-002198. PMID: 33963012
50. Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Borley A, Schmidt M, Rautenberg B, Kunze CA, Rhein U, Mehta K, Mousa K, Dibble T, Lu XL, von Minckwitz G, Bliss JM; Randomized European Celecoxib Trial (REACT) Trial Management Group and **Investigators**. (2021): Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. *JAMA Oncol*. 2021 Sep 1;7(9):1291-1301.
DOI: 10.1001/jamaoncol.2021.2193. PMID: 34264305

2022

51. Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, **Uleer C**, Warm M, Fischer HH, Malter W, Hauptmann M, Kates RE, Gräser M, Würstlein R, Shak S, Baehner F, Kreipe HH, Harbeck N. (2022) Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. *J Clin Oncol*. 2022 Aug 10;40(23):2557-2567.
DOI: 10.1200/JCO.21.02759. Epub 2022 Apr 11. PMID: 35404683
52. **Christoph Uleer**, Edward Wight, Birgitt van Oorschot, Joan Elisabeth Panke, Timm Dauelsberg, Anne Letsch, Kerstin Paradies, Reina Tholen, Heidemarie Haase, Joachim Weis (2022) Nachsorge, Rezidivbehandlung, psychoonkologische Aspekte, Rehabilitation, Physiotherapie und Palliativversorgung des Endometriumkarzinoms. *Die Gynäkologie* 05.07.2022 55; 509-515
DOI: 10.1007/s00129-022-04960-3

53. Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; **WSG-ADAPT investigators** (2022) De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol.* 2022 May;23(5):625-635. doi: 10.1016/S1470-2045(22)00159-0. Epub 2022 Apr 8. PMID: 35405088
54. Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, **Uleer C**, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, Jóźwiak K, Zu Eulenburg C, Kreipe HH, Harbeck N. (2022) De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial. *Clin Cancer Res.* 2022 Jul 7;ccr.22.0482. DOI: 10.1158/1078-0432.CCR-22-0482. Online ahead of print. PMID: 35797219
55. Kolberg-Liedtke C, Feuerhake F, Garke M, Christgen M, Kates R, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, **Uleer C**, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Graeser M, Nitz U, Kreipe H, Gluz O, Harbeck N. (2022) Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. *Breast Cancer Res.* 2022 Sep 2;24(1):58. DOI: 10.1186/s13058-022-01552-w. PMID: 36056374.
56. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsayf F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓP, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martínez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and **Investigators**. (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Ann Oncol.* 2022 Dec;33(12):1250-1268. DOI: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. PMID: 36228963.
57. Schüler K, Bethmann D, Kaufhold S, Hartung C, Stückerath K, Lantzsich T, **Uleer C**, Hanf V, Peschel S, John J, Pöhler M, Buchmann J, Bürrig KF, Weigert E, Thomssen C, Kantelhardt EJ, Vetter M. (2022) Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. *Diagnostics (Basel).* 2022 Oct 18;12(10):2527. DOI: 10.3390/diagnostics12102527. PMID: 36292215.
58. Reinhardt K, Stückerath K, Hartung C, Kaufhold S, **Uleer C**, Hanf V, Lantzsich T, Peschel S, John J, Pöhler M, Bauer M, Bürrig FK, Weigert E, Buchmann J, Kantelhardt EJ, Thomssen C, Vetter M. (2022) PIK3CA-mutations in breast cancer. *Breast Cancer Res Treat.* 2022 Dec;196(3):483-493. DOI: 10.1007/s10549-022-06637-w. Epub 2022 Oct 24. PMID: 36279023.

B. Kongressbeiträge/Abstracts

1996

1. **C. Uleer**, H. G. Meerpohl (1996): Terapia del dolore in pazienti affette da un tumore ginecologico; principi di trattamento e aspetti etici. Vortrag auf dem Jahreskongress der italienischen Gerichtsmediziner in Modena, Italien: „Sessualita' e Diritto“

2000

2. F. Hilpert, T. Zeiser, S. Markmann, J. Quaas, T. Menschlik, A. Nugent, S. Buchholz, S. Flachsenberg, H. J. Bettex, **C. Uleer**, J. Pfisterer für die AGO-Studiengruppe Ovarialkarzinom, Sektion Nord (2000): Epirubicin/Carboplatin/Taxol vs. Carboplatin/Taxol als 1st-line Chemotherapie beim fortgeschrittenen Ovarialkarzinom. Interimsanalyse einer randomisierten Phase III-Studie der AGO-Studiengruppe Ovarialkarzinom

2008

3. **C. Uleer**, J. Y. Pourfard (2008): Klinische Sonderfälle in der interdisziplinären Brustkonferenz Senologie, Abstracts der 28. Jahrestagung der Deutschen Gesellschaft für Senologie #147

2009

4. U. Nitz, C. Oberhoff, T. Reimer, C. Schumacher, J. Hackmann, M. Warm, **C. Uleer**, V. Runde, O. Gluz, I. Zuna (2009): Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from the phase III ARA plus trial. Cancer Res 2009; 69(2 Suppl): SABCS 2008 Abstract nr 4100

2010

5. E.-J. Kantelhardt, V. Hanf, F. Weiß, C. Ehrke, T. Lantzsch, **C. Uleer**, K.-F. Bürrig, C. Thomssen (2010) PIA-Studie - Prognosefaktoren im Alltag bei Patientinnen mit neu diagnostiziertem operable Mammakarzinom: Risikoabschätzung anhand der Prognosemarker uPA/PAI-1. Senologie, Abstracts der 30. Jahrestagung der Deutschen Gesellschaft für Senologie # 75
6. Degenhardt T., Gluz O., Thomssen C., Vetter M., Kates R., Warm M., Shak S., Augustin D., Kusche M., Untch M., Paepcke S., **Uleer C.**, Dünnebacke J. Nitz U., Harbeck N. (2010): Risk Group Selection in Primary Breast Cancer According to ASCO Recommended Biomarkers Oncotype DX and uPA and PAI-1: First Experience from Prospective Multicenter WSG Plan B Trial. Cancer Res 2011; 70(2 Suppl): SABCS 2010 Abstract nr P2-09-05

2011

7. **C. Uleer**, J. Yazdan Pourfard, V. Möbus (2011): Das dosisdichte und dosisintensivierte ETC-Chemotherapieprotokoll in der gynäkologisch-onkologischen Praxis Abstracts der 31. Jahrestagung der Deutschen Gesellschaft für Senologie #078
8. Witzel ID, Loibl S, von Minckwitz G, Abdallah A, Kühn T, Overkamp F, Fehm T, Schrader I, **Uleer C**, Kohls A, Stirnberg S, zu Eulenburg C, Untch M, Müller V (2011) Predictive Value of HER2 Predictive Value of HER2 Serum Levels in Patients Treated with Lapatinib or Trastuzumab – A Translational Project in the Neoadjuvant “Geparquinto” Trial Cancer Research 2011, 71 (27) Suppl. SABCS 6.-10.12.2011 # P4-08-01
9. Nitz U, Gluz O, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, **Uleer C**, Runde V, Kümmel S, Zuna I, Harbeck N (2011) Adjuvant Chemotherapy with or without Darbepoetin alpha in Node Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial Cancer Research 2011, 71 (27) Suppl. SABCS 6.-10.12.2011 #PD 0706
10. Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, Shak S, Clemens M, Markmann S, **Uleer C**, Augustin D, Thomssen C, Nitz U, Harbeck N (2011) Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial Cancer Research 2011, 71 (27) Suppl. SABCS 6.-10.12.2011 #S4-3

2012

11. Oleg Gluz, Hans Heinrich Kreipe, Matthias Christgen, Tom Degenhardt, Ronald E. Kates, Cornelia Liedtke, Steven Shak, Michael R. Clemens, Marwa Salem, Susanne Markmann, Bernd Liedtke, Bahriye Aktas, Stephan Henschen, Anke Pollmanns, Petra Krabisch, **Christoph Uleer**, Doris Augustin, Christoph Thomssen, Ulrike Nitz, Nadia Harbeck (2012) Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial. J Clin Oncol 30, 2012 (suppl; abstr 552) 2012
12. Gluz O, Kreipe HH, Kates RE, Christgen M, Liedtke C, Shak S, Clemens M, Salem M, Liedtke B, Aktas B, Markmann S, **Uleer C**, Augustin D, Thomssen C, Nitz U, Harbeck N (2012) Prospective Comparison of Recurrence Score and Different Definitions of Luminal Subtypes by Central Pathology Assessment of Single Markers in Early Breast Cancer: Results from the Phase III WSG-planB Trial Cancer Research 2012, 17 72:P2-10-08; DOI:10.1158/0008-5472.SABCS12-P2-10-08

2013

13. V.r Moebus, H. Forstbauer, G. Wachsmann, A. Schneeweiss, A. Ober, E. von Abel, P. Krabisch, H.-G. Hoeffkes, K. Kast, B. Christensen, M. Niedermeier, M. Deryal, **C. Uleer**, Y. Fauster, T. Goehler, S. Loibl, V. Nekljudova, G. von Minckwitz, (2013): Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2). ASCO MEETING ABSTRACTS Jun 17, 2013:TPS1137
14. Von Schumann R, Gluz O, Hofmann D, Kates RE, Clemens M, Reimer T, Liedtke B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi, **Uleer C**, Krabisch P, Augustin D, Harbeck N, Nitz U (2013): Febrile Neutropenien (FN) und Infektionen unter adjuvanter Chemotherapie des Mammakarzinoms mit 6xTC vs. 4xEC-4xDoc: Toxizitätsdaten der WSG planB Studie 33. Jahrestagung der dt. Gesellschaft für Senologie # 90
15. Wuerstlein R, Gluz O, Kreipe HH, Kates RE, Christgen M, Liedtke C, Shak S, Clemens M, Salem M, Liedtke B, Aktas B, Markmann S, **Uleer C**, Augustin D, Hofmann D, Thomssen C, Nitz U, Harbeck N. WSG plan-B trial: Comparison of recurrence score and definitions of luminal subtypes 2013 St. Gallen International Breast Cancer Conference # 151

2014

16. F. Hilpert, P. Wimberger, J. Sehouli, A. Reuß, P. Harter, R. Hils, N. de Gregorio, H.-J. Lück, B. Gerber, T. Fehm, L. Hanker, **C. Uleer**, A. Burges, J. Kosse, M. Thill, M. Beckmann, J.-P. Scharf, W. Meier, G. Gebauer, E. Pujade-Lauraine (2014): Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). Deutscher Krebskongress 2014
17. Lüftner D, Schütz F, Grischke E, Fasching P, Wimberger P, Förster F, Decker T, **Uleer C**, Muth M, Kreuzeder J, Bloch W, Tesch H, Jackisch C (2014): Breast Cancer Treatment with Everolimus and Exemestane for ER+ Women - Results of the first interim analysis of the oninterventional trial BRAWO. ASCO-Meeting Abstract # ID 578
18. C. Jackisch, E.-M. Grischke, A. Schneeweiss, T. Decker, **C. Uleer**, F. Förster, O. Tomé, P. Wimberger, C. M Kurbacher, B. Mueller, N. Harbeck, C.h Mundhenke, S. Kuemmel, M. Muth, J. Kreuzeder, W. Bloch, H. Tesch, D. Lüftner, F. Schütz, P. A Fasching (2014): Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women". 37. CTRC-AACR San Antonio Breast Cancer Symposium
19. Martina Vetter, Kristin Reinhardt, Silke Wegener, Juergen Dittmer, Tilmann Lantzsch, **Christoph Uleer**, Susanne Peschel, Jutta John, Volker Hanf, Joerg Buchmann, Karl-Friedrich Bürrig, Edith Weigert, Christoph Thomssen, Eva J Kantelhardt (2014): Abstract P1-04-06: Prevalence of PIK3CA mutations in tumor tissue of a consecutive cohort of breast cancer patients (n=700). 37. CTRC-AACR San Antonio Breast Cancer Symposium

20. Fasching P A, Decker T, Schneeweiss A, **Uleer C**, Förster F, Wimberger P, Kurbacher CM, Harbeck N, Tome' O., Müller B, Mundhenke C, Kümmel S, Muth M, Kreuzeder J, Bloch W, Tesch H, Lüftner D, Jackisch C, Schütz F, Grischke E (2014): Breast cancer treatment with everolimus and exemestane for ER+ women - Results of the 2nd interim analysis of the noninterventional trial BRAWO. ESMO Conference Abstract # LBA9

2015

21. Oleg Gluz · Ulrike Nitz · Matthias Christgen · Eva-Maria Grischke · Helmut Forstbauer · Michael Wilhelm Braun · Mathias Warm · **Christoph Uleer** · Bahriye Aktas · Claudia Schumacher · [...] · Thill M · Kohls A · Kümmel S · Perlova-Griff L · Cornelia Liedtke · Hofmann D · Kates RE · Rachel Wuerstlein · Hans Heinrich Kreipe · Nadia Harbeck · (2015) Efficacy of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial. 2015 ASCO Annual Meeting [Abstract No: 506]
22. **C Uleer**, J Yazdan Pourfard, C Moisisidis-Tesch, G von Minckwitz (2015): Fallbericht: Langzeitüberleben eines Her2 positiven, metastasierten Mammakarzinoms durch eine Trastuzumab-haltige Kombinationsbehandlung nach dem Therapieprinzip „TBP“. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2015; 12 - A141, DOI: 10.1055/s-0035-1550583
23. Bloch W, Baumann F, Zimmer P, Grischke E M, Fasching PA, Decker T, **Uleer C**, Schneeweiss A, Salat C, Wimberger P, Mundhenke C, Förster F, Kluth-Pepper B, Schubert J, Tesch H, Schütz F, Lüftner D, Jackisch C (2016): Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO; Cancer Research 76(4 Suppl): P4-13-07

2017

24. S. Bernhardt, M. Bayerlová, M. Vetter, A. Wachter, D. Mitra, V. Hanf, T. Lantzsch, **C. Uleer**, S. Peschel, J. John, J. Buchmann, E. Weigert, K.-F. Bürrig, C. T., U. Korf, T. Beissbarth, S. Wiemann and E. J. Kantelhardt; Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors; Breast Cancer Research 2017;19:112; DOI:10.1186/s13058-017-0905-7
25. Nadia Harbeck, Oleg Gluz, Michael R. Clemens, Wolfram Malter, Toralf Reimer, Benno Nuding, Bahriye Aktas, Andrea Stefek, Anke Pollmanns, Fatemeh Lorenz-Salehi, **Christoph Uleer**, Petra Krabisch, Sherko Kummel, Cornelia Liedtke, Steven Shak, Rachel Wuerstlein, Matthias Christgen, Ronald Kates, Hans Heinrich Kreipe, Ulrike Nitz (2017): Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer; ASCO-Meeting Juni 2017: J Clin Oncol 35, 2017 (suppl; abstr 504)
26. Oleg Gluz, Cornelia Liedtke, Aleix Prat, Matthias Christgen, Daniel Gebauer, Ronald E. Kates, Eva-Maria Grischke, Helmut Forstbauer, Michael Wilhelm Braun, Mathias Warm, John Hackmann, **Christoph Uleer**, Bahriye Aktas, Claudia Schumacher, Sherko Kummel, Rachel Wuerstlein, Enrico Pelz, Ulrike Nitz, Hans Heinrich Kreipe, Nadia Harbeck (2017): Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial; ASCO-Meeting Juni 2017: J Clin Oncol 35, 2017 (suppl; abstr 573)
27. Peter A. Fasching, Eva-Maria Grischke, Florian Schuetz, Thomas Decker, **Christoph Uleer**, Christoph Salat, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Pauline Wimberger, Bahriye Aktas, Mark-Oliver Zahn, Oliver Tome, Wilhelm Bloch, Sven Hanson, Thomas Fischer, Joerg Schubert, Diana Lueftner (2017): Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO. ASCO-Meeting Juni 2017; J Clin Oncol 35, 2017 (suppl; abstr 1061)

28. Christian Jackisch, Peter A. Fasching, Eva-Maria Grischke, Florian Schuetz, Thomas Decker, **Christoph Uleer**, Christoph Salat, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Pauline Wimberger, Bahriye Aktas, Mark-Oliver Zahn, Oliver Tome, Wilhelm Bloch, Sven Hanson, Joerg Schubert, Diana Lueftner (2017): Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO. ASCO-Meeting Juni 2017; J Clin Oncol 35, 2017 (suppl; abstr e12547)
29. O. Gluz, U. Nitz, M. Christgen, W. Malter, M. Clemens, T. Reimer, B. Nuding, B. Aktas, A. Stefek, A. Pplmanns, F. Lorenz-Salehi, **C. Uleer**, P. Krabisch, S. Kümmel, C. Liedtke, S. Shak, R. Kates, R. Wurstlein, H.H. Kreipe, N. Harbeck (2017): Prognostic impact of Recurrence Score (RS), grade/Ki67 central pathological review, and anthracycline (A)-free vs. A-containing chemotherapy (CT) ; ESMO congress 2017 Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440 abstr. LBA 11

2018

30. Cornelia Liedtke, Friedrich Feuerhake, Madlen Garke, Matthias Christgen, Ronald E. Kates, Eva-Maria Grischke, Helmut Forstbauer, Michael Wilhelm Braun, Mathias R. Warm, Christoph Hackmann, **Christoph Uleer**, Bahriye Aktas, Claudia Schumacher, Sherko Kummel, Rachel Wuerstlein, Ulrike Nitz, Hans Heinrich Kreipe, Oleg Gluz, Nadia Harbeck (2018): Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial; ASCO-Meeting 2018: J Clin Oncol 36, 2018 (suppl; abstr 12102)
31. Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, Matthias Christgen, Eva-Maria Grischke, Helmut Forstbauer, Michael Wilhelm Braun, Mathias Warm, John Hackmann, **Christoph Uleer**, Bahriye Aktas, Claudia Schumacher, Nikola Bangemann, Christoph Lindner, Sherko Kummel, Ronald E. Kates, Rachel Wuerstlein, Hans Heinrich Kreipe, Nadia Harbeck (2018): Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial; ASCO-Meeting 2018: J Clin Oncol 36, 2018 (suppl; abstr 573)
32. O. Gluz, U. Nitz, C. Liedtke, M. Christgen, E. Grischke, H. Forstbauer, M. BRAUN, M. Warm, J. Hackmann, **C. Uleer**, B. Aktas, C. Schumacher, C. Lindner, S. Kümmel, R.E. Kates, J. Potenberg, P. Staib, R. Wuerstlein, H.H. Kreipe, N. Harbeck (2018): Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial; ESMO Congress 2018, Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy424.002, <https://DOI.org/10.1093/annonc/mdy424.002>
33. **C. Uleer** (2018): Downsizing der adjuvanten Therapie für Brustkrebspatientinnen aus dem Mammographie-Screening; Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGOG), abstr. 502 Geburtshilfe und Frauenheilkunde; Ausgabe 10, 2018
34. D Lüftner, F Schuetz, A Schneeweiss, E-M Grischke, W Bloch, T Decker, **C Uleer**, C Salat, F Förster, M Schmidt, C Mundhenke, H Tesch, C Jackisch, T Fischer, G Guderian, S Hanson and P Fasching (2018): Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO; SABCS 2018 Poster Session; DOI: 10.1158/1538-7445.SABCS18-P6-18-08; Published February 2019

2019

35. Martina Vetter, Carolin Hartung, Tilmann Lantzsich, Volker Hanf, **Christoph Uleer**, Susanne Peschel, Jutta John, Joerg Buchmann, Edith Weigert, Karl-Friedrich Buerrig, Eva-Johanna Kantelhardt and Christoph Thomssen (2019): Prospective analysis of molecular subtypes in triple negative breast cancer; SABCS 2019 Poster Session; DOI: 10.1158/1538-7445.SABCS19-P4-06-13; Published February 2020

36. Claudia Biehl, Cornelia Kolberg-Liedtke, Oleg Gluz, Friedrich Feuerhake, Matthias Christgen, Ronald Kates, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, **Christoph Uleer**, Bahriye Aktas, Claudia Schumacher, Sherko Kuemmel, Sanne L de Haas, Regula Deurloo, Rachel Wuerstlein, Ulrike Nitz, Hans H. Kreipe, Nadia Harbeck and West German Study Group (2019); Impact of immune markers on response to neoadjuvant de-escalated T-DM1 or trastuzumab with/or without endocrine therapy in HR+/HER2+ early breast cancer: A translational subproject of the WSG-ADAPT-HER2+/HR+ trial; SABCS 2019 Poster Spotlight Session; DOI: 10.1158/1538-7445.SABCS19-PD5-10; Published February 2020

2020

37. M. Schmidt, T. Degenhardt, P.A. Fasching, D. Lüftner, V. Müller, C. Thomssen, C. Schem, I. Witzel, T. Decker, H. Tesch, S. Kümmel, **C. Uleer**, R. Würstlein, O. Hoffmann, M. Warm, N. Marschner, R.E. Kates, J. Schumacher, N. Harbeck (2020): Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (PreCycle, NCT03220178); EJC 2020; Posters A: advanced Disease | Volume 138, Supplement 1, S68; DOI: 10.1016/S0959-8049(20)30709-7 Published October 01, 2020